The medicines below contain the following active ingredient: sulthiame. You can select a medicine from this list to find out more - including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS).
Product defect alert
Consumers and health professionals are advised that Phebra Pty Ltd, in consultation with the TGA, has initiated a product defect alert for bottles of Ospolot (sulthiame) 200 mg tablets.
The affected batch numbers are:
- 18003717 (expiry 05/21)
- 28811 (expiry 11/22)
Ospolot (sulthiame) 200 mg tablets are used as an anticonvulsant for behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks and Jacksonian seizures.
Consumer advice: If you or someone you care for is taking Ospolot (sulthiame) 200 mg tablets, check the batch number displayed on the bottle label.
If the bottle is from an affected batch, Phebra Pty Ltd, in consultation with the TGA, strongly recommends that extra vigilance and caution be exercised when storing this medicine. As per the product label and information, it is imperative that you keep the medicine out of reach of children.
More information: For more details and the latest updates, see TGA's alert on Ospolot (sulthiame) tablets 200 mg. Product Defect Alert — child-resistant caps may not function correctly.